Shares of PTC Therapeutics Inc. (PTCT) surged over 5% on Monday morning after Barclays raised its price target on the biopharmaceutical company's stock.
Barclays analyst X raised their price target on PTC Therapeutics to $43 from $31 while maintaining an Equal Weight rating. The increased price target follows the company's recent promising financial results and pipeline updates.
PTC Therapeutics is a leading global biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for rare diseases. Investors are optimistic about the company's prospects given its strong product portfolio and drug pipeline targeting diseases with high unmet medical need.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。